Phase 2/3 Immunology & Autoimmune Deal Benchmarks
Market Analysis
Phase 2/3 immunology & autoimmune licensing deals carry a median total deal value of $2.5B, with upfront payments ranging from $326M to $775M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 22% to upfront and 78% to milestones.
The immunology & autoimmune landscape at the phase 2/3 stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $291M, regulatory milestones contribute $620M, and commercial milestones reach $1.0B. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.
Royalty rates for phase 2/3 immunology & autoimmune deals range from 15.3% to 25.2% at the base tier, with high-tier escalation to 29.2%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for phase 2/3 immunology & autoimmune deals?
How are phase 2/3 immunology & autoimmune deal milestones structured?
What royalty rates are typical for phase 2/3 immunology & autoimmune licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.